Early detection and treatment of diabetic nephropathy

Pediatric Endocrinology Reviews

Volumn 5, Issue SUPPL. 4, 2008, Pages 999-1004

  Woredekal, Yalemzewd ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Diabetic kidney disease; Diabetic nephropathy; Prevention; Treatment

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CALCIMIMETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRON; PHOSPHATE BINDING AGENT; RECOMBINANT ERYTHROPOIETIN; VITAMIN D;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEVELOPED COUNTRY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; EARLY DIAGNOSIS; FAMILY HISTORY; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MICROALBUMINURIA; MORTALITY; PATHOGENESIS; PROTEINURIA; RISK FACTOR; SCREENING;

DIABETIC NEPHROPATHIES; HUMANS; INCIDENCE; MASS SCREENING; TIME FACTORS; UNITED STATES;

EID: 54949140364     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. US Renal Data System. ESRDS 2007 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda MD 2007
2. Gimeno Orna JA, Boned Juliani B, Lou Arnal LM, Castro Alonso FJ. Microalbuminuria and clinical proteinuria as the main predictive factors of cardiovascular morbidity and mortality in patients with type 2 diabetes. Rev Clin Esp 2003;203:526-531
3. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000; 160:1093-1100
4. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004;66:1596-1605
5. Krakoff J, Lindsay RS, Looker HC, Nelson RG, Hanson RL, Knowler WC. Incidence of retinopathy and nephropathy in youth-onset compared with compared with adult-onset type 2 diabetes. Diabetes Care 2003;26:76-81
6. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J, Linköping Diabetes Complication Study. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type I diabetes - the Linköping Diabetes Complication Study. Diabetologia 2004;47:1266-1272
7. Hovind P, Tarnow I, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving HH. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003;26:1258-1264
8. Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care 2003;26:2392-2399
9. Seaquist E, Goetz F, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320:1161-1165
10. Canani LH, Gerchman F, Gross JL, Familial clustering of diabetic nephropathy in Brazilian type 2 diabetic patients. Diabetes 1999;48:909-913
11. Mogensen CE, Schmitz O. The diabetic kidney: from hyperfiltration and microalbuminuria to end stage renal failure. Med Clin North Am 1988;72:1465-1492
12. Amin R, Widmer B, Prevost A, Schwarze P, Cooper J, Edge J, Marcovecchio L, Neil A, Dalton R, Bunger D. Risk of microalbuminuria and progression to macroalbuminuria in a cohort with childhood onset type 1 diabetes: prospective observational study. BMJ 2008;336:697-701
13. Hovind P, Tarnow L, Rossing P, Jensen B, Graae M, Torp I, Binder C, Parving H. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004; 328:1105-1110
14. Remuzzi G, Schieppapati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. New Engl J Med 2002;346:1145-1151
15. Chiken RL, Eckert-Norton M, Bard M, Banerji MA, Palmisaano J, Sachimechi I, Lebovitz HE. Hyperfiltration in African-American patients with type 2 diabetes. Cross-sectional and longitudinal data. Diabetes Care 1998;21;2129-2134
16. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent diabetic patients. N Engl J Med 1984;311:89-93
17. Christensen CK, Christiansen JS, Schmitz A, Christensen T, Hemansen K, Mogensen CE. Effect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients: a 2 year controlled study. J Diabet Complications 1987;1:91-95
18. Chiarelli F, Verrotti A, Morgese G. Glomerular hyperfiltration increases the risk of developing microalbumiuria in diabetic children. Pediatr Nephrol 1995;9:154-158
19. Gaede P Tarnow L, Vedel P Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004;19:2784-2788
20. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Morgensen CE, Parving HH, Steffes MW; American Diabetic Association: Nephropathy in diabetes. Diabetes Care 2004;27(Suppl 1).579-584
21. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: and indicator of more advanced glomerular lesions. Diabetes 2003;52:1036-1040
22. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273-3277
23. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient? Diabetes 2000;49:1399-1408
24. The Diabetes Control and Complication Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
25. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 1998;352:837-853
26. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003;290:2159-2167
27. American Diabetes Association. Position Statement: Standards of medical care for patients with diabetes mellitus. Diabetes Care 1999;22(Suppl 1):S32-S41
28. Tarnow L, Rossing P, Gall MA, Nielsen FS, Parving HH. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994;17:1247-1251
29. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Intern Med 2003;254:45-66
30. Parving HH. Is antihypertensive treatment the same for NIDDM and IDDM patients? Diabetes Res Clin Pract 1998;39(Suppl 1):S43-S47
31. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS, 38. BMJ 1998;317:703-713
32. Rachmani R, Levi Z, Slavachevsky I, Half-Onn E, Ravid M. Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorthiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. Nephron 1998;80:175-182
33. Lewis EJ, Huniscker LF, Bain RP, Rohde RD. The effect of angiotensin- converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462
34. Brenner BM, Cooper Me, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
35. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259
36. Rossing K, Jacobsen P, Pietraszek, L, Parving HH. Renoprotective effects of adding angiotensin II receptor biocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003;26:2268-2274
37. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomized controlled trial of dual blockade of renin- angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-1444
38. Joint National Committee. The sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-2446
39. American Diabetes Association. Diabetic Nephropathy. Diabetes Care 1999:22:S66-S69
40. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committee Working Group. Am J Kidney Dis 2000;36:646-661
41. Bosch JP, Saccaggi A, Lauer A, Ranco C, Belledonne M, Glabman S. Renal function reserve in humans. Effect of protein intake on glomerular filtration rate. Am J Med 1983;75:943-950
42. Kupin WL, Cortes P, Dumler F, Feldkamp CS, Kilates MC, Levin NW. Effect on renal function of change from high to moderate protein intake in type 1 diabetic patients. Diabetes 1987;36(1):73-79
43. Zeller K, Whittaker E, Sullivan L, Raskin P, Jacobson HR. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Engl J Med 1991;324:78-84
44. Meloni C, Tatangelo P, Cipriani S, Rossi V, Suraci C, Tozzo C, Rossinin B, Cecilia A, DiFranco D, Straccialano E, Casciani CU. Adequate protein restriction in diabetic and nondiabetic patients with chronic renal failure. J Ren Nutr 2004; 14:208-213
45. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002;62:220-228
46. Toeller M, Buyken AE. Protein intake-new evidence for its role in diabetic nephropathy. Nephro Dial Transplant 1998;13:1926-1927
47. Thomas MC, Rosengard-Bartund M, Mitls V, Ronnback M, Thomas S, Forsblom C, Cooper ME, Taskinen MR, Viberti G, Groop PH. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 2006;29:317-322
48. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, Holl RW. Diabetic nephropathy in 27,805 children, adolescents and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset and gender. Diabetes Care 2007;30:2523-2528
49. Hadjadj S, Duty-Bouhanick B, Bekherraz A, Bridoux F, Gallois Y, Mauco G, Ebran J, Marre M. Serum triglycerides are a predictor factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab 2004;30:43-51
50. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 2001;59:260-269
51. American Diabetes Association: Clinical Practice Recommendations 2008. Diabetes Care 2008; 31 (Supl):S8-S9
52. Sawicki PT, Didjurgeit U, Muhthauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy. Diabetes Care 1994; 17:126-131
53. Chuahirun T, Khanna A, Kimball K, Wesson DE. Cigarette smoking and increased urine albumin excretion are interrelated predictors of nephropathy progression in type 2 diabetes. Am J Kidney Dis 2003;41:13-21
54. Chuahirun T, Simoni J, Hudson S, Seipel T, Khanna A, Harrist RB, Wesson DE. Cigarette smoking exacerbates and its cessation ameliorates renal injury in type 2 diabetes. Am J Med Sci 2004;327:57-67